Esketamine - Johnson & Johnson

Drug Profile

Esketamine - Johnson & Johnson

Alternative Names: JNJ-54135419; S-ketamine

Latest Information Update: 06 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Johnson & Johnson
  • Class Analgesics; Antidepressants; Chlorobenzenes; Cyclohexanones; General anaesthetics; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Major depressive disorder

Most Recent Events

  • 15 Jun 2017 Phase-III clinical trials in Major depressive disorder (Adjunctive treatment) in USA, Argentina, Austria, Belgium, Brazil, Canada, Czech Republic, France, Lithuania, Poland, Turkey, United Kingdom (Intranasal) (NCT03097133)
  • 12 Jun 2017 Janssen Research & Development plans a phase II trial for Major depressive disorder (Adjunctive treatment, In adolescents) in USA, Belgium, France, Brazil, Bulgaria, Hungary, Poland and Spain (Intranasal) (NCT03185819)
  • 09 Jun 2017 Janssen Research & Development initiates the phase III Aspire I trial for Major depressive disorder (Adjunctive treatment) in USA (Intranasal) (NCT03039192)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top